MarketPulse

cardiovascular therapeutics

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Amarin Posts 7% Revenue Growth in Q1 2026 Amid Strong VASCEPA Momentum

Amarin reports Q1 2026 revenue of $45.1M (up 7%), narrows operating losses 33%, maintains debt-free balance with $307.8M cash.
RICFYrevenue growthinternational expansion
GlobeNewswire Inc.GlobeNewswire Inc.··Unknown

Unnatural Products Lands $45M Series B, Novartis Deal Worth $1.7B

Biotech startup Unnatural Products secures $45M Series B funding led by The Venture Collective and inks $1.7B milestone deal with Novartis for oral peptide therapeutics.
MRKARGXNVSmacrocyclic peptidesSeries B funding